New shot aims to calm immune attack on kidneys

NCT ID NCT05668403

Recruiting now Disease control Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called B007, given as a shot under the skin, for people with primary membranous nephropathy — a kidney disease where the immune system attacks the kidneys. The study will include 52 adults and will focus on safety, how the drug moves through the body, and whether it shows any early signs of helping. Because it is a Phase 1 trial, the main goal is to find a safe dose, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: B007 (a lab-made antibody that targets CD20 on immune cells)
What this could lead to: If it works, this could point toward a new treatment option for primary membranous nephropathy that is easier to take (as a shot under the skin).
What could go wrong: This is a very early Phase 1 trial with only 52 people, focused on safety and dosing. It is too soon to know if the drug will actually help the disease, and there may be side effects from targeting immune cells.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic membranous glomerulonephritis membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY MEMBRANOUS NEPHROPATHY

Contacts and locations

Show contact details

Locations

Hebei General Hospital
RECRUITING

Shijiazhuang, Hebei, 050057, China
Longhua Hospital Shanghai University of Traditional Chinese Medicine
RECRUITING

Shanghai, 200032, China
Longhua Hospital Shanghai University of Traditional Chinese Medicine
RECRUITING

Shanghai, 200032, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
Peking university first hospital
RECRUITING

Beijing, 100010, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, He'nan, 410100, China
The First Affiliated Hospital,College of Medicine,Zhejiang University
RECRUITING

Hangzhou, Zhejiang, 310003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.